» Articles » PMID: 34451862

Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue

Overview
Publisher MDPI
Specialty Chemistry
Date 2021 Aug 28
PMID 34451862
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals' lives. NDs have complex etiologies but commonly feature altered gene expression and dysfunctions of the essential chromatin-modifying factors. Hence, compounds that target DNA and histone modification pathways, the so-called epidrugs, constitute promising tools to treat NDs. Yet, targeting the entire epigenome might reveal insufficient to modify a chosen gene expression or even unnecessary and detrimental to the patients' health. New technologies hold a promise to expand the clinical toolkit in the fight against NDs. (Epi)genome engineering using designer nucleases, including CRISPR-Cas9 and TALENs, can potentially help restore the correct gene expression patterns by targeting a defined gene or pathway, both genetically and epigenetically, with minimal off-target activity. Here, we review the implication of epigenetic machinery in NDs. We outline syndromes caused by mutations in chromatin-modifying enzymes and discuss the functional consequences of mutations in regulatory DNA in NDs. We review the approaches that allow modifying the (epi)genome, including tools based on TALENs and CRISPR-Cas9 technologies, and we highlight how these new strategies could potentially change clinical practices in the treatment of NDs.

Citing Articles

Integrative computational analyses implicate regulatory genomic elements contributing to spina bifida.

Wolujewicz P, Aguiar-Pulido V, Thareja G, Suhre K, Elemento O, Finnell R Genet Med Open. 2024; 2:101894.

PMID: 39669613 PMC: 11613821. DOI: 10.1016/j.gimo.2024.101894.


SWI/SNF Complex Connects Signaling and Epigenetic State in Cells of Nervous System.

Chmykhalo V, Deev R, Tokarev A, Polunina Y, Xue L, Shidlovskii Y Mol Neurobiol. 2024; 62(2):1536-1557.

PMID: 39002058 DOI: 10.1007/s12035-024-04355-6.


CTCF shapes chromatin structure and gene expression in health and disease.

Dehingia B, Milewska M, Janowski M, Pekowska A EMBO Rep. 2022; 23(9):e55146.

PMID: 35993175 PMC: 9442299. DOI: 10.15252/embr.202255146.

References
1.
Maeder M, Angstman J, Richardson M, Linder S, Cascio V, Tsai S . Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013; 31(12):1137-42. PMC: 3858462. DOI: 10.1038/nbt.2726. View

2.
Sams D, Nardone S, Getselter D, Raz D, Tal M, Rayi P . Neuronal CTCF Is Necessary for Basal and Experience-Dependent Gene Regulation, Memory Formation, and Genomic Structure of BDNF and Arc. Cell Rep. 2016; 17(9):2418-2430. DOI: 10.1016/j.celrep.2016.11.004. View

3.
Heigwer F, Kerr G, Boutros M . E-CRISP: fast CRISPR target site identification. Nat Methods. 2014; 11(2):122-3. DOI: 10.1038/nmeth.2812. View

4.
Kieffer-Kwon K, Nimura K, Rao S, Xu J, Jung S, Pekowska A . Myc Regulates Chromatin Decompaction and Nuclear Architecture during B Cell Activation. Mol Cell. 2017; 67(4):566-578.e10. PMC: 5854204. DOI: 10.1016/j.molcel.2017.07.013. View

5.
Maiti A, Drohat A . Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem. 2011; 286(41):35334-35338. PMC: 3195571. DOI: 10.1074/jbc.C111.284620. View